Post hoc analysis of three randomised trials showing semaglutide produces similar weight loss in MASLD and MASH regardless of type 2 diabetes status or cardiometabolic risk. PICO summary and expert commentary.
Browsing: Semaglutide
Evidence summaries for semaglutide across type 2 diabetes, obesity, cardiovascular outcomes, kidney outcomes, safety, dosing, and comparative therapy.
Replacing mealtime insulin with weekly semaglutide missed its primary glycaemic target (90% vs 75%, p=0.18) but cut weight and insulin dose in this small open-label trial. PICO summary and expert commentary.
A prespecified STRIDE subgroup analysis examined whether once-weekly semaglutide 1.0 mg improves walking distance consistently across diabetes characteristics in 792 adults with symptomatic PAD and type 2 diabetes. PICO summary and expert commentary.
An industry-sponsored indirect treatment comparison suggesting tirzepatide 10 and 15 mg achieve greater weight, BMI and HbA1c reduction than semaglutide 2.4 mg in type 2 diabetes, with no head-to-head trial. PICO summary and expert commentary.
A post hoc analysis of SUSTAIN China asked whether baseline traits modify the glycaemic effect of once-weekly semaglutide versus sitagliptin in type 2 diabetes. PICO summary and expert commentary.
An RCT finds adding semaglutide to metformin improves weight, testosterone, and natural pregnancy rates in women with PCOS. PICO summary and expert commentary.
A small 52-week single-centre randomised trial found once-weekly semaglutide shifted lipoprotein subfractions toward a less atherogenic profile versus sitagliptin in type 2 diabetes. PICO summary and expert commentary.
Clinical Context GLP-1 receptor agonists produce substantial weight loss, but the mechanisms underlying this effect have been debated. Is weight…
Clinical Context Heart failure with preserved ejection fraction (HFpEF) represents one of the most challenging conditions in cardiovascular medicine. Unlike…
Summary: In 1,145 patients with obesity-related HFpEF (LVEF ≥45%, BMI ≥30 kg/m²) from the pooled STEP-HFpEF trials, semaglutide 2.4 mg…